BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tritschler L, Felice D, Colle R, Guilloux J, Corruble E, Gardier AM, David DJ. Vortioxetine for the treatment of major depressive disorder. Expert Review of Clinical Pharmacology 2014;7:731-45. [DOI: 10.1586/17512433.2014.950655] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
Number Citing Articles
1 Frampton JE. Vortioxetine: A Review in Cognitive Dysfunction in Depression. Drugs 2016;76:1675-82. [DOI: 10.1007/s40265-016-0655-3] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 6.8] [Reference Citation Analysis]
2 Tomaz VS, Chaves Filho AJM, Cordeiro RC, Jucá PM, Soares MVR, Barroso PN, Cristino LMF, Jiang W, Teixeira AL, de Lucena DF, Macedo DS. Antidepressants of different classes cause distinct behavioral and brain pro- and anti-inflammatory changes in mice submitted to an inflammatory model of depression. J Affect Disord 2020;268:188-200. [PMID: 32174477 DOI: 10.1016/j.jad.2020.03.022] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 21.0] [Reference Citation Analysis]
3 Zheng G, Xue W, Yang F, Zhang Y, Chen Y, Yao X, Zhu F. Revealing vilazodone's binding mechanism underlying its partial agonism to the 5-HT1A receptor in the treatment of major depressive disorder. Phys Chem Chem Phys 2017;19:28885-96. [PMID: 29057413 DOI: 10.1039/c7cp05688e] [Cited by in Crossref: 28] [Cited by in F6Publishing: 13] [Article Influence: 9.3] [Reference Citation Analysis]
4 Felice D, Guilloux JP, Pehrson A, Li Y, Mendez-David I, Gardier AM, Sanchez C, David DJ. Vortioxetine Improves Context Discrimination in Mice Through a Neurogenesis Independent Mechanism. Front Pharmacol 2018;9:204. [PMID: 29593535 DOI: 10.3389/fphar.2018.00204] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
5 Saltiel PF, Silvershein DI. Major depressive disorder: mechanism-based prescribing for personalized medicine. Neuropsychiatr Dis Treat 2015;11:875-88. [PMID: 25848287 DOI: 10.2147/NDT.S73261] [Cited by in Crossref: 11] [Cited by in F6Publishing: 28] [Article Influence: 1.8] [Reference Citation Analysis]
6 Zimmerman M, Clark HL, Multach MD, Walsh E, Rosenstein LK, Gazarian D. Inclusion/exclusion criteria in placebo-controlled studies of vortioxetine: Comparison to other antidepressants and implications for product labeling. J Affect Disord 2016;190:357-61. [PMID: 26546771 DOI: 10.1016/j.jad.2015.10.041] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
7 Ragi NC, Velma GR, Pallerla PK, Siddiqua S, Alugonda V, Rachamalla HKR, Pabbaraja S, Sripadi P. Identification and characterization of forced degradation products of vortioxetine by LC/MS/MS and NMR. J Pharm Biomed Anal 2020;188:113442. [PMID: 32622114 DOI: 10.1016/j.jpba.2020.113442] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Zabegalov KN, Kolesnikova TO, Khatsko SL, Volgin AD, Yakovlev OA, Amstislavskaya TG, Alekseeva PA, Meshalkina DA, Friend AJ, Bao W, Demin KA, Gainetdinov RR, Kalueff AV. Understanding antidepressant discontinuation syndrome (ADS) through preclinical experimental models. European Journal of Pharmacology 2018;829:129-40. [DOI: 10.1016/j.ejphar.2018.04.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
9 Wang S, Han C, Pae C. Criticisms of drugs in early development for the treatment of depression: what can be improved? Expert Opinion on Investigational Drugs 2015;24:445-53. [DOI: 10.1517/13543784.2014.985784] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
10 Farooq RK, Tanti A, Ainouche S, Roger S, Belzung C, Camus V. A P2X7 receptor antagonist reverses behavioural alterations, microglial activation and neuroendocrine dysregulation in an unpredictable chronic mild stress (UCMS) model of depression in mice. Psychoneuroendocrinology 2018;97:120-30. [DOI: 10.1016/j.psyneuen.2018.07.016] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 10.3] [Reference Citation Analysis]